Qiagen NV (XTER:QIA) Other Financing: €-62 Mil (TTM As of Mar. 2026)


XTER:QIA Qiagen NV XTER:QIA
76 GF Score
Price €36.41
GF Value €45.89
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Qiagen NV Other Financing?

Qiagen NV XTER:QIA -0.72% 76 Other Financing is €-62 Mil as of Mar. 2026. GuruFocus rates XTER:QIA with a GF Score™ of 76/100 and a GF Value™ of €45.89 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Qiagen NV's Other Financing for the three months ended in Mar. 2026 was €0 Mil.

Qiagen NV's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-62 Mil.

Qiagen NV Other Financing Historical Data

* Premium members only.

The historical data trend for Qiagen NV's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV Other Financing Chart

Qiagen NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.00 -16.40 2.54 -22.42 -284.28

Qiagen NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -59.97 -1.74 0.00
XTER:QIA
76GF Score
Qiagen NV XTER:QIA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qiagen NV Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-62 Mil mean?
Qiagen NV (XTER:QIA) has a Other Financing of €-62 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Qiagen NV and its competitors.
Is Qiagen NV's Other Financing too high?
Qiagen NV's current Other Financing is €-62 Mil. Overall, Qiagen NV has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Other Financing compare to TWST and CRL?
Qiagen NV's Other Financing of €-62 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Diagnostics & Research company?
A good Other Financing depends on the Medical Diagnostics & Research industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Qiagen NV and its competitors. Qiagen NV's current Other Financing is €-62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.89, compared to a current price of €36.41 — trading 20.7% below its estimated fair value. The current Other Financing is €-62 Mil. Qiagen NV's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Other Financing is €-62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qiagen NV (XTER:QIA) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €36.41 is trading 20.7% below its estimated GF Value™ of €45.89. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for XTER:QIA:

  • Other Financing: €-62 Mil
  • GF Value™: €45.89 vs. price of €36.41 (20.7% below fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
76GF Score

Get the complete analysis for XTER:QIA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€36.41
Price
€45.89
GF Value